These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9046072)

  • 1. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex.
    Pehek EA
    Synapse; 1996 Sep; 24(1):12-8. PubMed ID: 9046072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
    Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex.
    Pehek EA; Bi Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):671-82. PubMed ID: 9194148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex.
    Nomikos GG; Iurlo M; Andersson JL; Kimura K; Svensson TH
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):147-56. PubMed ID: 7862887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
    Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
    Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of dopamine release by striatal 5-HT2C receptors.
    Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
    Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.
    Schmidt CJ; Fadayel GM
    Eur J Pharmacol; 1995 Feb; 273(3):273-9. PubMed ID: 7737334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.
    Pehek EA; Nocjar C; Roth BL; Byrd TA; Mabrouk OS
    Neuropsychopharmacology; 2006 Feb; 31(2):265-77. PubMed ID: 15999145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex.
    Pehek EA; McFarlane HG; Maguschak K; Price B; Pluto CP
    Brain Res; 2001 Jan; 888(1):51-59. PubMed ID: 11146051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
    Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The characterization of the effect of locally applied N-methylquipazine, a 5-HT3 receptor agonist, on extracellular dopamine levels in the anterior medial prefrontal cortex in the rat: an in vivo microdialysis study.
    Kurata K; Ashby CR; Oberlender R; Tanii Y; Kurachi M; Rini NJ; Strecker RE
    Synapse; 1996 Dec; 24(4):313-21. PubMed ID: 10638822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin.
    Devaud LL; Hollingsworth EB; Cooper BR
    J Neurochem; 1992 Oct; 59(4):1459-66. PubMed ID: 1402896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism.
    Ichikawa J; Dai J; Meltzer HY
    Brain Res; 2005 Jul; 1049(2):182-90. PubMed ID: 15936730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.
    Bortolozzi A; Masana M; Díaz-Mataix L; Cortés R; Scorza MC; Gingrich JA; Toth M; Artigas F
    Int J Neuropsychopharmacol; 2010 Nov; 13(10):1299-314. PubMed ID: 20158933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.
    Li Z; Ichikawa J; Meltzer HY
    Psychopharmacology (Berl); 2003 May; 167(3):315-23. PubMed ID: 12664192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations.
    Johnson M; Sonsalla PK; Letter AA; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1994 Jul; 270(1):97-103. PubMed ID: 7913500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the 5-HT2 receptor antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens.
    Devaud LL; Hollingsworth EB
    Eur J Pharmacol; 1991 Jan; 192(3):427-9. PubMed ID: 1675992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
    Ago Y; Nakamura S; Baba A; Matsuda T
    Neuropsychopharmacology; 2005 Jan; 30(1):43-51. PubMed ID: 15383832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens.
    Di Matteo V; Di Giovanni G; Di Mascio M; Esposito E
    Neuropharmacology; 1998; 37(2):265-72. PubMed ID: 9680252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.
    Ruiu S; Marchese G; Saba PL; Gessa GL; Pani L
    Mol Psychiatry; 2000 Nov; 5(6):673-7. PubMed ID: 11126398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.